Biolargo Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Biolargo Inc (BLGO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Biolargo Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 139,874M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+22.3% annualized vs trailing 12 months), vs accelerating (+5.9%) for its tracked peer group.
- Growth: Biolargo Inc generated -55.1% revenue growth year over year in Q2 2026, vs 18.0% for its competitors combined.
- Profitability: Its -320.5% net margin compares with 4.5% for the peer group.
- Scale: Biolargo Inc ranks #69 of 81 companies by market capitalization in the Chemical Manufacturing industry, holding 0.0% of industry market cap.
- Peer revenue share: Biolargo Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.09M compares with $0.66M for the peer group (0.1x).
- Structure: Biolargo Inc operates in the following segments: BioLargo Engineering Science Technologies LLC, Odor No More, BioLargo Canada, Corporate and Unallocated.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BLGO Sales vs. its Competitors, Q2 2026
Biolargo Inc reported revenue contraction of 55.06 % year on year in Q2 2026, below its competitors' combined revenue growth of 17.97 %.
With a net margin of -320.51 %, Biolargo Inc reported lower profitability than its competitors (4.53 %).
Biolargo Inc generated 0.00 % of the combined sales of its peer group, down from 0.01 % a year earlier.
API endpoints for this dataset
Biolargo Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Biolargo Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Biolargo Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Biolargo Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Biolargo Inc's competitor groups requires a Commercial License.
For context: the Chemical Manufacturing industry grew revenue 1.9% year over year, combined, vs -55.1% for Biolargo Inc. Biolargo Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Biolargo Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Biolargo Inc | - | No | No | Yes |
| Competitors combined (7) | ||||
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BLGO Stock Performance relative to its Competitors
BLGO Stock Performance relative to High-Confidence Competitors
BLGO Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Enviri Corp | 282.9% | Outperformed |
| 2 | Clean Harbors inc | 282.9% | Outperformed |
| 3 | Republic Services Inc | 282.9% | Outperformed |
| 4 | Eqt Corporation | 282.9% | Outperformed |
| 5 | Tesla Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Biolargo Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Biolargo Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Biolargo Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Biolargo Inc |
25.81 | 4.08 |
 Tesla Inc |
1,317,570.69 | 103,570.00 |
 Republic Services Inc |
75,401.50 | 18,529.00 |
 Eqt Corporation |
31,395.68 | 9,347.14 |
 Clean Harbors inc |
15,165.04 | 6,563.69 |
 Enviri Corp |
688.00 | 1,866.97 |
| SUBTOTAL | 1,440,252.31 | 139,877.93 |
Sign in to see all competitors of Biolargo Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Biolargo Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Biolargo Inc's Competitors Named by the Company
Competitive relationships identified from Biolargo Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Tesla | Company report | 85% |
| Republic Services | Company report | 85% |
| Enviri Corporation | Company report | 85% |
| Clean Harbors | Company report | 85% |
| CATL (Contemporary Amperex Technology Co.) | Company report | 85% |
| OMI Industries | Company report | 85% |
| Atmos Technologies | Company report | 85% |
| Xylem | Company report | 85% |
| Chemstation | Company report | 85% |
| Panasonic | Company report | 85% |
| Veolia | Company report | 85% |
| BYD (Build Your Dreams) | Company report | 85% |
| MANLY | Company report | 85% |
| AECOM | Company report | 85% |
| Pentair | Company report | 85% |
| Weaver Consulting Group | Company report | 85% |
| Covanta | Company report | 85% |
| U.S. Ecology | Company report | 85% |
| Clean Earth | Company report | 85% |
| Heritage Environmental Services | Company report | 85% |
| Circon Holdings, Inc. | Company report | 85% |
| EQT Infrastructure | Company report | 85% |
| Eqt Corporation | Company report | 85% |
| Alternus Clean Energy Inc | Company report | 85% |
| Lithium Corporation | Company report | 85% |
| Waste Management Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Biolargo Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Biolargo Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Biolargo Inc | BioLargo Engineering Science Technologies LLC 87.34 % |
| Tesla Inc | Automotive 89.73 % |
| Republic Services Inc | Group 1 45.96 % |
| Eqt Corporation | Upstream 92.08 % |
| Clean Harbors inc | Environmental Services 82.29 % |
| Enviri Corp | Harsco Environmental 46.69 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Biolargo Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Biolargo Inc | 26 | 88,739 | -408,500 |
| Tesla Inc | 1,317,571 | 768,409 | 24,202 |
| Republic Services Inc | 75,401 | 441,167 | 53,013 |
| Eqt Corporation | 31,396 | 6,137,322 | 1,832,183 |
| Clean Harbors inc | 15,165 | 290,544 | 23,388 |
| Enviri Corp | 688 | 155,580 | -42,418 |
| PEERS TOTAL | 1,440,226 | 656,996 | 38,904 |
Biolargo Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Tesla Inc | United States 44.55 % |
| Clean Harbors inc | United States 91.38 % |
| Enviri Corp | North America 59.02 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Biolargo Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 76 companies in Biolargo Inc's industry classification, broader than the peer set above. Market cap in millions of $.Biolargo Inc ranks #69 of 76 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,447, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Linde Plc | 239,708 | 46.67 % |
| 2 | Air Products And Chemicals Inc | 68,536 | 13.34 % |
| 3 | Ppg Industries Inc | 27,880 | 5.43 % |
| 4 | International Flavors and Fragrances Inc | 21,567 | 4.20 % |
| 5 | Lyondellbasell Industries N v | 1,234 | 5.2% |
| 6 | Rpm International Inc | 1,234 | 5.2% |
| 7 | Westlake Corporation | 1,234 | 5.2% |
| 8 | Corteva Inc | 1,234 | 5.2% |
| 9 | Axalta Coating Systems Ltd | 1,234 | 5.2% |
| 10 | Element Solutions Inc | 1,234 | 5.2% |
| 69 | Biolargo Inc | 26 | 0.01 % |
Market cap and industry share for the rest of Biolargo Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Biolargo Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 64 | Liquidmetal Technologies Inc | 67 | -47.79 % |
| 65 | Lanzatech Global Inc | 58 | -72.25 % |
| 66 | Citrotech Inc | 55 | - |
| 67 | Blue Biofuels Inc | 37 | -35.43 % |
| 68 | Xcf Global Inc | 1,234 | 12.3% |
| 69 | Biolargo Inc | 26 | -49.75 % |
| 70 | Verde Clean Fuels Inc | 1,234 | 12.3% |
| 71 | Tomi Environmental Solutions Inc | 1,234 | 12.3% |
| 72 | Loop Industries Inc | 1,234 | 12.3% |
| 73 | Pure Bioscience Inc | 1,234 | 12.3% |
| 74 | Gulf Resources Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Biolargo Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Biolargo Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Chemical Manufacturing industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (116 companies). See the full Chemical Manufacturing industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 39.93 % | 22.63 % (avg) | +17.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | 1.56 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 5.83 % | 7.75 % (avg) | -1.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Biolargo Inc's Valuation vs Competitive Position
Valuation multiples vs the Chemical Manufacturing industry average (116 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Chemical Manufacturing industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 13.4x | - |
| P/B | 95.3x | 3.8x | +91.4x |
| Return on Equity | -4,120.83 % | industry aggregate | -4,124.60 % |
| Return on Invested Capital | -754.26 % | -0.80 % (avg) | -753.46 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Biolargo Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 164.23 % | 36.44 % | 30.68 % | 4.07 % | 132.48 % | 106.56 % | 46.28 % | -56.32 % |
| Operating Margin | -470.09 % | -359.81 % | -311.80 % | -254.29 % | -91.60 % | -37.68 % | -24.36 % | - |
| Return on Invested Capital | 348.67 % | - | 211.08 % | 2,948.91 % | -272.70 % | -71.22 % | -39.41 % | -180.71 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Biolargo Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Biolargo Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 2.4% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Linde Plc alone holds 47% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Biolargo Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 2,447 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 5.83 % vs industry average 7.75 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Biolargo Inc's dedicated Suppliers and Customers pages, not here.
Biolargo Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Biolargo Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Biolargo Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+22.3% annualized vs trailing 12 months).
Weaknesses
- Return on equity 4,124.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Linde Plc, holding 46.67 % of industry market cap.
Methodology: see Methodology: SWOT Analysis.
Biolargo Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Biolargo Inc | 0.81 | 1.09 | 3.15 |
| Tesla Inc | 0.47 | 1.96 | 0.05 |
| Republic Services Inc | 0.03 | 0.67 | 1.74 |
| Eqt Corporation | 0.08 | 0.70 | 0.11 |
| Clean Harbors inc | - | 2.18 | 0.97 |
| Enviri Corp | 0.23 | 1.22 | 3.07 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Biolargo Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Biolargo Inc | Q2 2026 | -55.1 % | - |
| Tesla Inc | Q3 2026 | -0.2 % | -43.3 % |
| Republic Services Inc | Q3 2026 | +23.6 % | +7.6 % |
| Eqt Corporation | Q3 2026 | -9.6 % | -31.6 % |
| Clean Harbors inc | Q3 2026 | +20.7 % | +75.2 % |
| Enviri Corp | Q2 2026 | -66.7 % | - |
| PEERS TOTAL | +1.9 % | -39.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Biolargo Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Biolargo Inc | Q2 2026 | -57.7 % | - |
| Tesla Inc | Q3 2026 | -2.1 % | +110.5 % |
| Republic Services Inc | Q3 2026 | +8.1 % | +11.5 % |
| Eqt Corporation | Q3 2026 | -1.7 % | +3.4 % |
| Clean Harbors inc | Q3 2026 | +15.2 % | +83.5 % |
| Enviri Corp | Q2 2026 | -68.5 % | -11.2 % |
Biolargo Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Biolargo Inc | - | - | - |
| Tesla Inc | 2.22% | 3.04% | 3.80% |
| Republic Services Inc | 6.38% | 5.96% | 18.47% |
| Eqt Corporation | 6.71% | 5.99% | 9.79% |
| Clean Harbors inc | 6.75% | 8.47% | 18.27% |
| Enviri Corp | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Biolargo Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Biolargo Inc | - | 6.32 |
| Tesla Inc | 408.89 | 12.72 |
| Republic Services Inc | 34.12 | 4.07 |
| Eqt Corporation | 12.08 | 3.36 |
| Clean Harbors inc | 28.81 | 2.31 |
| Enviri Corp | - | 0.37 |
| PEERS AVERAGE | 174.28 | 10.30 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.